Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia

被引:20
作者
Hiramatsu, Ippei [1 ,2 ]
Tsujimura, Akira [2 ]
Soejima, Miho [2 ]
Yoshiyama, Azusa [2 ]
Nagashima, Yuki [1 ,2 ]
Ishikawa, Keisuke [1 ,2 ]
Uesaka, Yuka [2 ]
Nozaki, Taiji [2 ]
Ogishima, Tatsuya [2 ]
Shirai, Masato [2 ]
Mitsuhashi, Isao [2 ]
Sugimura, Sosuke [2 ]
Mizuno, Taiki [2 ]
Noto, Kensho [2 ]
Shigeta, Yasuhiro [3 ]
Takasu, Jiro [4 ]
Honda, Shinichi [5 ]
Iwata, Shinji [2 ]
Horie, Shigeo [1 ]
机构
[1] Juntendo Univ, Grad Sch Med, Dept Urol, Tokyo, Japan
[2] Juntendo Univ, Urayasu Hosp, Dept Urol, 2-1-1 Tomioka, Chiba 2790021, Japan
[3] Nishi Funabashi Urol Clin, Dept Urol, Funabashi, Chiba, Japan
[4] Urayasu Cent Hosp, Dept Urol, Chiba, Japan
[5] Yatsu Hoken Hosp, Dept Urol, Narashino, Chiba, Japan
关键词
benign prostatic hyperplasia; chronic prostatitis; chronic pelvic pain syndrome; lower urinary tract symptom; National Institutes of Health Chronic Prostatitis Symptom Index; tadalafil; URINARY-TRACT SYMPTOMS; HISTOLOGICAL PROSTATITIS; DOUBLE-BLIND; INFLAMMATION; MEN; MULTICENTER; PROGRESSION; PREVALENCE; TAMSULOSIN; MECHANISM;
D O I
10.1111/iju.14122
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To investigate the efficacy of tadalafil for patients with benign prostatic hyperplasia and chronic prostatitis/chronic pelvic pain syndrome. Methods Tadalafil 5 mg was given each morning for 12 weeks to patients diagnosed as having either moderate or severe lower urinary tract symptoms. Voiding symptoms were compared between patients with a high (>= 4; high group) and low (<4; low group) pain subscore of the National Institutes of Health Chronic Prostatitis Symptom Index before and after tadalafil administration. The correlation between changes in the Chronic Prostatitis Symptom Index and the International Prostate Symptom Score during treatment was also investigated. Results At baseline, the pain subscore of the Chronic Prostatitis Symptom Index was high (>= 4) in 24 of 74 (32.4%) patients. The International Prostate Symptom Score in the group with a high pain subscore was significantly higher than that in the group with a low pain subscore. International Prostate Symptom Score, National Institutes of Health Chronic Prostatitis Symptom Index total score and pain subscore were all significantly improved after treatment. The change in the Chronic Prostatitis Symptom Index total score correlated positively with the change in the International Prostate Symptom Score. The decrease in the International Prostate Symptom Score was significantly greater in the group with high versus low pain subscore. Conclusions Tadalafil is sufficiently effective in the treatment of patients with benign prostatic hyperplasia and severe chronic prostatitis/chronic pelvic pain syndrome.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 25 条
[1]   Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome - A randomized, double-blind trial [J].
Alexander, RB ;
Propert, KJ ;
Schaeffer, AJ ;
Landis, JR ;
Nickel, JC ;
O'Leary, MP ;
Pontari, MA ;
McNaughton-Collins, M ;
Shoskes, DA ;
Comiter, CV ;
Datta, NS ;
Fowler, JE ;
Nadler, RB ;
Zeitlin, SI ;
Knauss, JS ;
Wang, YL ;
Kusek, JW ;
Nyberg, LM ;
Litwin, MS .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (08) :581-589
[2]   Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis chronic pelvic pain syndrome [J].
Alexander, RB ;
Ponniah, S ;
Hasday, J ;
Hebel, JR .
UROLOGY, 1998, 52 (05) :744-749
[3]   Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia [J].
Anjum, I ;
Ahmed, M ;
Azzopardi, A ;
Mufti, GR .
JOURNAL OF UROLOGY, 1998, 160 (03) :792-793
[4]   Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome A Systematic Review and Network Meta-analysis [J].
Anothaisintawee, Thunyarat ;
Attia, John ;
Nickel, J. Curtis ;
Thammakraisorn, Sangsuree ;
Numthavaj, Pawin ;
McEvoy, Mark ;
Thakkinstian, Ammarin .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (01) :78-86
[5]   Prevalence of chronic prostatic inflammation based on clinical diagnostic criteria in a real-practice setting: a nation-wide observational study [J].
Fusco, Ferdinando ;
Arcaniolo, Davide ;
Restaino, Anna ;
Lauri, Irene ;
Franzese, Corrado .
MINERVA UROLOGICA E NEFROLOGICA, 2017, 69 (05) :509-518
[6]   The role of prostatic inflammation in the development and progression of benign and malignant diseases [J].
Gandaglia, Giorgio ;
Zaffuto, Emanuele ;
Fossati, Nicola ;
Cucchiara, Vito ;
Mirone, Vincenzo ;
Montorsi, Francesco ;
Briganti, Alberto .
CURRENT OPINION IN UROLOGY, 2017, 27 (02) :99-106
[7]   Mechanism of Phosphodiesterase 5 Inhibitor relief of Prostatitis Symptoms [J].
Grimsley, S. J. S. ;
Khan, M. H. ;
Jones, G. E. .
MEDICAL HYPOTHESES, 2007, 69 (01) :25-26
[8]   Clinical Significance of IL-2, IL-10, and TNF-α in Prostatic Secretion of Patients With Chronic Prostatitis [J].
He, Leye ;
Wang, Yong ;
Long, Zhi ;
Jiang, Chonghe .
UROLOGY, 2010, 75 (03) :654-657
[9]   NIH consensus definition and classification of prostatitis [J].
Krieger, JN ;
Nyberg, L ;
Nickel, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (03) :236-237
[10]   The Effect of Intraprostatic Chronic Inflammation on Benign Prostatic Hyperplasia Treatment [J].
Kwon, Young Kee ;
Choe, Mi Sun ;
Seo, Kyung Won ;
Park, Chol Hee ;
Chang, Hyuk Soo ;
Kim, Byung Hoon ;
Kim, Chun Il .
KOREAN JOURNAL OF UROLOGY, 2010, 51 (04) :266-270